Lung cancer originates in the lungs, and there are two major types of lung cancer which are; non-small cell lung cancer, and small cell lung cancer. People with smoking habit have greatest risk of developing lung cancer. Second hand smoke, family history, and exposure to certain toxins are few of the other reasons behind development of lung cancer. 
Non-small cell lung cancer is a common form of lung cancer and subcategorized into squamous cell carcinoma, adenocarcinoma and large cell carcinoma. Diagnosis of lung cancer includes imaging, biopsy, and treatment includes radiotherapy, surgery, chemotherapy, immunotherapy, and targeted drug therapy among others. 

Market Drivers and Restraints:

• Increasing prevalence of lung cancer
  • According to American Cancer Society (ASC), in 2022, there were ~236,740 new cases of lung cancer (117,910 in men and 118,830 in women) in the US.
  • Furthermore, approximately 84% of the lung cancer cases are of NSCLC, and rest 14% are of small cell lung cancer
• Global Non-small cell lung cancer market has a wide and robust research and development pipeline. Leading as well as small to medium size organizations are developing novel therapies for the treatment of the disease.
• Global Non-small cell lung cancer treatment landscape has seen several regulatory drug approvals, and products launches over past few years which has fuelled growth of the global Non-small cell lung cancer market.

Non-small Cell Lung Cancer Epidemiology:

Global Non-small Cell Lung Cancer Treatment Market accounted for US$ 24.1 Bn in 2022 and is expected to witness a CAGR of 8.9% over the forecast period (2022-2030) to reach US$ 47.5 Bn by 2030

Competitive Landscape:

The global non-small cell lung cancer treatment market is fairly consolidated with a few multinational corporations dominating in the industry. Key companies operating in the market are well-equipped with large manufacturing facilities and they are engaged in various research and development activities. 

We employ tools and techniques such as PEST analysis, SWOT analysis, PORTER’s analysis, BCG matrix to provide competitive and market intelligence.

Some of the prominent players operating in the market are:

• Pfizer Inc.
• AstraZeneca plc
• F. Hoffmann-La Roche Ltd.
• Eli Lilly and Company
• Boehringer Ingelheim GMBH
• Novartis International AG
• Bristol-Myers Squibb Company
• Merck & Co., Inc.
• Johnson & Johnson
• Amgen, Inc.

Segments covered in the global non-small cell lung cancer treatment market report:

The global non-small cell lung cancer treatment market is segmented based on treatment type, marketed brand , distribution channel, and region as follows:

• Treatment Type (Revenue, USD Billion; 2022–2030)
  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Others
• Marketed Brand (Revenue, USD Billion; 2022–2030)
  • Bevacizumab (Avastin)
  • Necitumumab (Portrazza)
  • Ramucirumab (Cyramza)
  • Nivolumab (Opdivo)
  • Atezolizumab (Tecentriq)
  • Others
• Distribution Channel (Revenue, USD Billion; 2022–2030)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Region (Revenue, USD Billion; 2022–2030)
  • North America 
    • U.S.
    • Canada
  • Europe 
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific 
    • China
    • Japan
    • South Korea
    • India
    • ASEAN
    • Rest of APAC
  • Latin America 
    • Brazil
    • Mexico
    • Rest of LATAM
  • Middle East & Africa 
    • Saudi Arabia
    • UAE
    • Rest of MEA